Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: A single institution case control study

Leukemia and Lymphoma

Volumn 51, Issue 3, 2010, Pages 399-405

  Johnston, Anna ^a,b   Bouafia Sauvy, Fadhela ^a   Broussais Guillaumot, Florence ^a   Michallet, Anne Sophie ^a   Traullé, Catherine ^a   Salles, Gilles ^a   Coiffier, Bertrand ^a  

^a HOSPICES CIVILS DE LYON   (France)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

B cell lymphoma; Refractory; Relapsed; Retreatment; Rituximab

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERFERON; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TENIPOSIDE; VINCRISTINE; VINDESINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; REFRACTORY B CELL LYMPHOMA; RELAPSED B CELL LYMPHOMA; RETREATMENT; CASE CONTROL STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 77249095877     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428190903503404     Document Type: Article

References (14)

1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007;26:3603-3613.
2. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-3071.
3. Conconi A, Martinelli G, Thieblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-2745.
4. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti- CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-3143.
5. Lemieux B, Bouafia F, Thieblemont C, et al. Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Haematol J 2004;5:467-471.
6. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma-a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005;23:1088-1095.
7. Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+NHL: a prospective randomized HOVON trial. Blood 2008;111: 537-543.
8. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large Bcell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93: 1829-1836.
9. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244.
10. Blay JY, Gomez F, Sebban C, et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998;92:3562-3568. (Pubitemid 28525180)
11. Kewalramani T, Zelenetz AD, Nimen SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-3688.
12. Borgerding A, Hasenkamp J, Glaß B, Wulf G, Trümper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol 2009 Sep 2. [Epub ahead of print].
13. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18: 1363-1368.
14. Gisselbrecht C, Schmitz N, Mounier N, et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. Blood 2007; 110(Suppl. 1):159a (Abstract 517).